印度的醫藥品委託製造：關注的機會 是由出版商RNCOS E-Services Pvt. Ltd.在2011年03月所出版的。
這份英文市場調查報告書包含65 Pages 價格從美金900起跳。
全球的醫藥品委託製造業界在近幾年大幅成長。印度以做為醫藥品製造委外服務的市場領導者而抬頭，其他各國也採用其模式。藥劑製造的委外服務對藥廠來說有許的優點。在經濟動向的變動和藥劑製造成本削減的壓力當中，印度的醫藥品委託製造市場預期在2011∼2013年將以CAGR45.5%擴大。
本報告，大範圍調查印度的醫藥品委託製造業界，彙整市場的現狀與將來動向、智慧財產權的保護和出口、資料保護的法律規範環境等，由下列摘要形式闡述。
第1章 分析師的見解
第2章 調查方式
第3章 市場概要
第4章 地區別展望與範圍
- 先進地區
- Gujarat
- Maharashtra
- Andhra Pradesh
- West Bengal
- 發展中地區
- Assam
- Himachal Pradesh
- orissa
第5章 市場分析
- 市場動向與促進因子
- 高品質產品與GMP規範的更進一步關注
- 醫藥品委外服務的支援性服務
- 生物製造的登場
- 合作：市場參與的偏好方式
- 現在的業界課題
第6章 法規環境
第7章 競爭分析
- Piramal Healthcare Limited
- Dishman Pharmaceuticals and Chemicals Ltd.
- Dr. Reddy's Laboratories Ltd.
- Jubilant Life Sciences
- Wockhardt Ltd.
圖表
Abstract
The global pharmaceutical contract manufacturing industry has registered
strong growth during the past few years. Amongst many other countries adopting
the model, India has emerged as a market leader in pharma outsourcing.
Outsourcing of drugs manufacturing provides many advantages for the
pharmaceutical companies, such as enhanced production capacity, easier access
to a large number of destination countries, and low scale up cost. Contract
manufacturing will help the pharmaceutical companies to meet with the growing
demand for new drugs and improve their core competencies.
According to our new research report “Indian Contract Manufacturing - A
Hot Opportunity”, the demand for contract manufacturing services in
India has been consistently rising due to the increasing cost pressure on
pharmaceutical companies. The recent global economic slowdown was also a major
factor for the adoption of contract manufacturing model. Leading pharma
companies in the market are also looking at this model as a means to expand
into the bio-similars and generics segment. With the changing economic
scenario and the pressure of reducing drugs manufacturing cost, Indian
contract manufacturing market is expected to grow at a CAGR of around 45.5%
during 2011-2013.
We have also found that pharma manufacturing process is highly developed in
some of the prominent states in the country, such as Gujarat and Maharashtra.
Thus, to present a clear picture, we have incorporated the regional analysis
of India along with the analysis of pharma market in the developed and
emerging states. Drugs manufactured by the contract manufacturing companies in
India are utilized for the local markets and exported to other major regions
in the Asia-Pacific region, Middle East, and Africa.
The report provides an extensive research and prudent analysis of the Indian
contract manufacturing industry. It gives an insight into the current and
future market trends, and provides a brief overview of the regulatory
environment in India regarding IP protection, export, and data protection. The
report has also studied key contract manufacturers in the countries to help
clients understand the overall market dynamics. The report will work as an
investment guide for the clients looking to invest or outsource their
manufacturing process in the Indian market.
Table of Contents
1. Analyst View
2. Research Methodology
3. Market Overview
4. Regional Outlook and Scope
- 4.1. Developed Regions
- 4.1.1. Gujarat
- 4.1.2. Maharashtra
- 4.1.3. Andhra Pradesh
- 4.1.4. West Bengal
- 4.2. Upcoming Regions
- 4.2.1. Assam
- 4.2.2. Himachal Pradesh
- 4.2.3. Orissa
5. Market Analysis
- 5.1. Market Trends and Drivers
- 5.1.1. More Focus on Quality Products and GMP Regulations
- 5.1.2. Supplementary Services in Pharma Outsourcing
- 5.1.3. Emergence of Bio Manufacturing
- 5.1.4. Collaboration: A Preferred Way of Market Penetration
- 5.2. Current Industry Issues
- 5.2.1. IP Issues
- 5.2.2. Quality Assurance Risk
- 5.2.3. Inefficient Project Handling and Delivery
6. Regulatory Environment
7. Competitive Analysis
- 7.1. Piramal Healthcare Limited
- 7.2. Dishman Pharmaceuticals and Chemicals Ltd.
- 7.3. Dr. Reddy' s Laboratories Ltd.
- 7.4. Jubilant Life Sciences
- 7.5. Wockhardt Ltd.
List of Figures:
- Figure 3-1: Pharma Outsourcing Services Market (Billion US$), 2008-2013
- Figure 3-2: Pharma Contract Manufacturing Market (Million US$), 2009-2013
- Figure 4-1: Regional Distribution of Pharmaceutical Manufacturing Units
(%), 2010
- Figure 4-2: Distribution of Pharmaceutical Clusters
- Figure 4-3: Distribution of WHO GMP Certified Manufacturing Units in
Gujarat (%)
- Figure 4-4: Share of Gujarat in US FDA Approved Companies (2010)
- Figure 4-5: Distribution of Schedule ‘M’ Compliant
Pharmaceutical Manufacturing Units in Maharashtra (%), 2009
- Figure 4-6: Share of Andhra Pradesh in Bulk Drugs Manufacturing
- Figure 4-7: Share of Andhra Pradesh in Bulk Drugs Export
List of Tables:
- Table 4-1: Summary of Issued and Commissioned Pharmaceutical Projects in
Gujarat
- Table 4-2: Potential Manpower Availability in Gujarat (2009)
- Table 4-3: Potential Manpower Availability in Maharashtra
- Table 4-4: Potential Manpower Availability in Andhra Pradesh (2009)
- Table 4-5: Potential Manpower Availability in West Bengal (2009)
- Table 7-1: Piramal Healthcare Limited - Strengths & Weaknesses
- Table 7-2: Dishman Pharmaceuticals and Chemicals Ltd - Strengths &
Weaknesses
- Table 7-3: Dr. Reddy' s Laboratories Ltd. - Strengths & Weaknesses
- Table 7-4: Jubilant Life Sciences Ltd - Strengths & Weaknesses
- Table 7-5: Wockhardt - Strengths & Weaknesses
